59.20 +0.29 (0.49%)
After hours: 7:42PM EDT
|Bid||58.52 x 900|
|Ask||59.30 x 1000|
|Day's range||58.37 - 59.58|
|52-week range||42.48 - 68.34|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||29.31|
|Earnings date||06 May 2020|
|Forward dividend & yield||1.80 (3.09%)|
|Ex-dividend date||01 Apr 2020|
|1y target est||70.45|
Bristol-Myers (BMY) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bristol Myers' (BMY) applications for Opdivo in combination with Yervoy administered concomitantly with a limited course of chemotherapy have been accepted in the United States and Europe.
BMS Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo Plus Yervoy Combined with Limited Chemotherapy in First-Line Lung Cancer
Bristol-Myers Squibb (BMY) closed the most recent trading day at $56.80, moving -1.85% from the previous trading session.
Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its existing patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic.
Bristol Myers (BMY) and Acceleron received FDA nod for the label expansion of Reblozyl for MDS patients who require RBC transfusions, failing an erythropoiesis stimulating agent.
FDA Approves Reblozyl®, the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
Fate Therapeutics (FATE) signs agreement with J&J subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company.
Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.
Bristol Myers Squibb & bluebird bio Announce Submission of BLA for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
BMS Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA for the Treatment....
The FDA bestows a Fast Track designation on Infinity's (INFI) IPI-549 in combination with Opdivo for treating advanced urothelial cancer. Stock rise.
Zacks.com featured highlights include: Bristol-Myers Squibb, AmerisourceBergen, Leidos, Xcel Energy and Caseys General Stores
NEJM Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis
The suspension by the China National Medical Products Administration was announced by partner Beigene Ltd and confirmed by Bristol-Myers on Wednesday. Beigene and Bristol-Myers were working to restore supply as soon as possible, said China-based Beigene, which signed an agreement with Bristol-Myers' Celgene unit in 2017 to market and distribute Abraxane. "This decision only applies to the China market and does not impact our ability to supply Abraxane outside of China," Bristol-Myers said in an emailed statement.